The nociceptin opioid (NOP) receptor is the most recently discovered member of the family of the opioid receptors; its endogenous agonist is the peptide nociceptin. Due to the subsequent elucidation of its physiological role in both central and peripheral nervous system and in some non-neural tissues, there is a rapidly growing interest in the pharmacological application of substances active on this receptor. Despite the current clinical use of a morphinane-based NOP/MOP mixed ligand (buprenorphine) as an analgesic and in the treatment of drug addictions, so far just a few clinical trials have been made with selective NOP ligands. However, the perspective of their utilization is rapidly growing. Agonists can find applications in the treatment of neuropathic pain, anxiety, cough, drug addition, urinary incontinence, anorexia, congestive heart failure, hypertension; and antagonists for pain, depression, Parkinson's disease, obesity, and as memory enhancers. Besides peptide ligands, which are still subjected to many pharmacological investigations, many different chemical classes of NOP ligands have been discovered: piperidines, nortropanes, spiropiperidines, 4-amino-quinolines and quinazolines, and others. The new advances in establishing structure-activity relationships, also with the help of modeling studies, can permit the development of more active and selective molecules.

No abstract

No abstract

No abstract

This paper describes the preparation of some pyrazolo[1,5-a]-, 1,2,4-triazolo[1,5-a]-and imidazo[1,2-a]pyrimidines substituted on the pyrimidine moiety by a 4- [(N-acetyl-N-ethyl)amino]phenyl group. A new synthesis of related benzo[h]pyrazolo[1,5-a]-, benzo[h]pyrazolo[5,1-b]-and benzo[h]1,2,4-triazolo[1,5-a]quinazolines is also reported.